All News

Sleep asleep

Dreaming of Relief: The Importance of Sleep in Lupus and Rheumatoid Arthritis

d Andrea Fava, MD

Sleep plays a critical role in regulating inflammation and overall health. In rheumatic diseases like lupus and rheumatoid arthritis (RA), disrupted sleep is common and can exacerbate symptoms and disease progression. Experts Dr. Al Kim, Patty Katz, and Dr. Yvonne Lee emphasized the importance of addressing sleep disturbances in these conditions.

Read Article
Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 2 Recap: #ACR24 Highlights Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush RheumNow ( View Tweet)

RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh

Links:

Dr. John Cush RheumNow ( View Tweet)
maze-1804499_1280.jpg

Methotrexate to Prevent RA, Clear as Mud

d Richard Conway, MBBChBAO, PhD

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.

Read Article
artificial intelligence machine learning computer

Predicting flares in rheumatic diseases with machine learning

d Antoni Chan, MD, PhD

Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.

Read Article
Prgnancy,outcome

Improving fertility in women with RA

d Jiha Lee, MD

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.

Read Article
Finding the Right Combination Therapy in RA Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu
Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm

Links:

Dr. John Cush RheumNow ( View Tweet)

Are we under-monitoring in scleroderma ILD? Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq
Dr. John Cush RheumNow ( View Tweet)
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld

Links:

Richard Conway RichardPAConway ( View Tweet)
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld

Links:

Richard Conway RichardPAConway ( View Tweet)
Does CVD mortality risk change after stopping GC in RA? ➡️28078 incident GC users ➡️Incr mortality risk from CVD &infections persists post-cessation ➡️Risk never returns to pre-GC level after prolonged use ⏩Use GC at lowest dose for shortest time possible Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Ab2674 #ACR24 ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12 ➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M @RheumNow https://t.co/pFOo86tJTx

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatment accordingly. #ACR24 @RheumNow ABST#2674 https://t.co/YTThYiiLpZ

Links:

Jiha Lee JihaRheum ( View Tweet)
#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

Links:

Janet Pope Janetbirdope ( View Tweet)
In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

Links:

sheila RHEUMarampa ( View Tweet)
Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.